Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Phase 2
294
about 4.5 years
18+
10 sites in AL, CA, FL +5
What this study is about
Researchers are testing a treatment (Volrustomig or Rilvegostomig) alone or with other cancer drugs to see if it helps people with advanced liver or bile duct cancer. The trial will last for about 1648 days and involve around 294 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Bevacizumab
- 2.Take Cisplatin
- 3.Take Gemcitabine
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bevacizumab, cisplatin (Platinum chemotherapy; crosslinks DNA to stop replication), gemcitabine, lenvatinib
infusion, injection, intravenous, injection (Injection), oral (Oral Capsule)
Primary: Objective response rate (ORR), Progression free survival (PFS), The number of participants with adverse events/serious adverse events
Secondary: Disease Control Rate (DCR), Duration Of Response (DOR), Objective response rate (ORR), Overall Survival (OS), Pharmacokinetics of novel immunomodulators: Maximum plasma concentration of the study drug (Cmax), Pharmacokinetics of novel immunomodulators: Time to maximum plasma concentration of the study drug (T-max), Progression free survival (PFS)